semaglutide injection ohio to end GLP-1 drug weight loss coverage for state workers Ohio calls out weight-loss drug

Future interdisciplinary efforts, including in-depth mechanistic studies, large multicenter long-term follow-up trials, and translational research on precise intervention targets, are needed to address these gaps

The ELIXA (Evaluation of LIXisenatide in Acute coronary syndromes) trial randomly assigned patients to receive lixisenatide (a GLP-1 RA) or placebo within 180 days from hospitalization for AMI (mean 72 days) [26]

(PubMed) Zhang H, Wang S, Tuo L, et al

Additional information Publisher'S Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations